Back to top
more

PetMed Express (PETS)

(Delayed Data from NSDQ)

$2.66 USD

2.66
62,719

+0.03 (1.14%)

Updated Sep 23, 2025 04:00 PM ET

After-Market: $2.68 +0.02 (0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 246)

Industry: Internet - Commerce

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Investors Should Buy Myriad Genetics Right Now

by Zacks Equity Research

Myriad Genetics' (MYGN) recent collaborations are encouraging. Also, the company banks on the GeneSight and EndoPredict portfolios.

    Zacks Equity Research

    Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx

    by Zacks Equity Research

    Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.

      Zacks Equity Research

      Myriad Genetics' Latest Alliance to Boost GeneSight Reach

      by Zacks Equity Research

      Myriad Genetics' (MYGN) tie-up with Department of VA to assess the effectiveness of GeneSight test buoys optimism. Also, favorable results might boost GeneSight's customer base

        Zacks Equity Research

        DaVita Issues Downbeat '17 View, Hurricanes Affect Q3 Results

        by Zacks Equity Research

        Hurricanes Harvey and Irma dealt a heavy blow to DaVita's (DVA) operating income in the third quarter. Management's tepid forecast for the full year adds to the concerns.

          Zacks Equity Research

          Here's Why Investors Should Buy Luminex (LMNX) Right Now

          by Zacks Equity Research

          Luminex (LMNX) continues to grow strong on innovation and product launches.

            Zacks Equity Research

            Haemonetics (HAE) Grows on Strong Plasma, Competition Rife

            by Zacks Equity Research

            Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.

              Zacks Equity Research

              Quest Diagnostics, Clinical Genomics Ally, Oncology Strong

              by Zacks Equity Research

              Quest Diagnostics' (DGX) plan to distribute Clinical Genomics' FDA-approved InSure ONE is in line with the company's objective to lead in the high-potential oncology diagnostic market.

                Zacks Equity Research

                Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025

                by Zacks Equity Research

                Weight Watchers' (WTW) plan to issue senior notes will aid the company in reducing cost of capital.

                  Zacks Equity Research

                  Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens

                  by Zacks Equity Research

                  Divestiture of certain businesses to Cardinal Health induces year-over-year decline in Medtronic's (MDT) preliminary sales figure. However, impact of Maria is likely to be lighter on the company's finances.

                    Zacks Equity Research

                    Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3

                    by Zacks Equity Research

                    Balanced growth across all geographical regions as well as many key life science and diagnostics product areas helps Bio-Rad (BIO) to drive the top and bottom line in Q3.

                      Zacks Equity Research

                      BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates

                      by Zacks Equity Research

                      A decline in gross and operating margin was a major drag for BioTelemetry (BEAT) in the third quarter.

                        Zacks Equity Research

                        Bruker's NANO Grows Strong, MERLIN Buyout Holds Promise

                        by Zacks Equity Research

                        Bruker's (BRKR) recent acquisition of Germany-based MERLIN buoys optimism for its growth within MALDI Biotyper business.

                          Zacks Equity Research

                          AmerisourceBergen (ABC) Rewards Investors With Dividend Hike

                          by Zacks Equity Research

                          AmerisourceBergen's (ABC) dividend hike adheres to the company's policy of rewarding stakeholders at regular intervals.

                            Zacks Equity Research

                            OPKO Health (OPK) Posts Wider-Than-Estimated Loss in Q3

                            by Zacks Equity Research

                            OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.

                              Zacks Equity Research

                              Inogen Claims Top Position in Deloitte List on Solid Growth

                              by Zacks Equity Research

                              Inogen's (INGN) unique direct-to-customer business model has lent it a leading position in the United States.

                                Zacks Equity Research

                                QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition

                                by Zacks Equity Research

                                QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.

                                  Zacks Equity Research

                                  TransEnterix (TRXC) Posts In-Line Loss in Q3, Sales Fall Y/Y

                                  by Zacks Equity Research

                                  TransEnterix's (TRXC) reports unimpressive Q3 results, thanks to the constriction of deferred service revenues.

                                    Zacks Equity Research

                                    Dull MFA & Mineral Nutrition Sales Hurt Phirbo, Rivalry Rife

                                    by Zacks Equity Research

                                    Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.

                                      Zacks Equity Research

                                      Hologic (HOLX) Q4 Earnings & Revenues Top, Margins Down

                                      by Zacks Equity Research

                                      Solid double-digit growth at Hologic's (HOLX) molecular diagnostics and international business drives the top line in Q4.

                                        Zacks Equity Research

                                        Genomic Health (GHDX) Swings to Earnings in Q3, Revenues Lag

                                        by Zacks Equity Research

                                        Genomic Health (GHDX) gains from strong adoption of its Oncotype DX test in Q3.

                                          Zacks Equity Research

                                          Hill-Rom (HRC) Banks on Product Launches, Competition Rife

                                          by Zacks Equity Research

                                          Hill-Rom (HRC) focuses on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging.

                                            Zacks Equity Research

                                            Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates

                                            by Zacks Equity Research

                                            At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.

                                              Zacks Equity Research

                                              Globus Medical (GMED) Q3 Earnings In Line, View Reiterated

                                              by Zacks Equity Research

                                              Globus Medical (GMED) reports in-line third-quarter numbers on the back of higher revenues from core international business.

                                                Zacks Equity Research

                                                Baxter Posts Solid Q3, Broad Product Spectrum Raises Hopes

                                                by Zacks Equity Research

                                                Baxter's (BAX) convenient kidney dialysis solutions, regenerative tissue products, 3-in-1 oXIRIS set for continuous renal replacement therapy are the latest additions to the extensive product portfolio.

                                                  Zacks Equity Research

                                                  SurModics (SRDX) Posts Earnings in Q4, Revenues Top Estimates

                                                  by Zacks Equity Research

                                                  SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.